Anti-ARHGAP45 antibody (STJA0009676)

SKU:
STJA0009676
£49.00 - £261.00
Processing The item has been added

Short Description :Rabbit polyclonal anti-Rho GTPase-activating protein 45 for use in WB in Human and Mouse samples. Datasheet included with dilution recommendations, and related reagents.
Applications:WB
Host:Rabbit
Reactivity:Human/Mouse
Note:STRICTLY FOR FURTHER SCIENTIFIC RESEARCH USE ONLY (RUO). MUST NOT TO BE USED IN DIAGNOSTIC OR THERAPEUTIC APPLICATIONS.
Clonality :Polyclonal
Isotype:IgG
Conjugation:Unconjugated
Concentration:1 mg/mL
Purification:The antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen.
Dilution Range:WB 1:500-2000
Formulation:Liquid in PBS containing 50% Glycerol, 0.5% BSA and 0.02% Sodium Azide.
Storage Instruction:Store at-20°C for up to 1 year from the date of receipt, and avoid repeat freeze-thaw cycles.
Gene Symbol:ARHGAP45
Gene ID:23526
Uniprot ID:HMHA1_HUMAN
Immunogen:Synthesized peptide derived from human HMHA1
Specificity:This antibody detects endogenous levels of HMHA1 at Human, Mouse
Function Contains a GTPase activator for the Rho-type GTPases (RhoGAP) domain that would be able to negatively regulate the actin cytoskeleton as well as cell spreading. However, also contains N-terminally a BAR-domin which is able to play an autoinhibitory effect on this RhoGAP activity. Precursor of the histocompatibility antigen HA-1. More generally, minor histocompatibility antigens (mHags) refer to immunogenic peptide which, when complexed with MHC, can generate an immune response after recognition by specific T-cells. The peptides are derived from polymorphic intracellular proteins, which are cleaved by normal pathways of antigen processing. The binding of these peptides to MHC class I or class II molecules and its expression on the cell surface can stimulate T-cell responses and thereby trigger graft rejection or graft-versus-host disease (GVHD) after hematopoietic stem cell transplantation from HLA-identical sibling donor. GVHD is a frequent complication after bone marrow transplantation (BMT), due to mismatch of minor histocompatibility antigen in HLA-matched sibling marrow transplants. Specifically, mismatching for mHag HA-1 which is recognized as immunodominant, is shown to be associated with the development of severe GVHD after HLA-identical BMT. HA-1 is presented to the cell surface by MHC class I HLA-A*0201, but also by other HLA-A alleles. This complex specifically elicits donor-cytotoxic T-lymphocyte (CTL) reactivity against hematologic malignancies after treatment by HLA-identical allogenic BMT. It induces cell recognition and lysis by CTL.
Protein Name Rho Gtpase-Activating Protein 45 Cleaved Into - Minor Histocompatibility Antigen Ha-1
Mhag Ha-1
Database Links Reactome: R-HSA-6798695
Reactome: R-HSA-8980692
Reactome: R-HSA-9013148
Reactome: R-HSA-9013149
Cellular Localisation Cytoplasm
Cell Projection
Ruffle Membrane
Alternative Antibody Names Anti-Rho Gtpase-Activating Protein 45 Cleaved Into - Minor Histocompatibility Antigen Ha-1 antibody
Anti-Mhag Ha-1 antibody
Anti-ARHGAP45 antibody
Anti-HMHA1 antibody
Anti-KIAA0223 antibody

Information sourced from Uniprot.org